Browse News
Filter News
Found 86 articles
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
RNAi Therapeutics Market Size to Climb USD 4.28 Billion by 2033
4/17/2024
The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.
-
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
-
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
10/10/2023
Merck, known as MSD outside of the United States and Canada, announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society for Medical Oncology Congress 2023 in Madrid, Spain, from Oct. 20-24.
-
COVID-19 vaccination: No serious side effects in young children
6/6/2023
A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children found no indications of serious side effects.
-
Drugs that act on the CFTR protein only work in patients who produce the protein in the first place. That leaves 6% of patients hanging.
-
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
5/15/2023
Merck, known as MSD outside of the United States and Canada, announced that data for four approved medicines and two pipeline candidates in more than 25 types of cancer will be presented at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago from June 2-6.
-
Merck Announces First-Quarter 2023 Financial Results
4/27/2023
First Quarter 2023 Reflected Continued Strong Underlying Performance Across Key Growth Drivers, Particularly in Oncology and Vaccines.
-
Research Roundup: New Target for Crohn's, Myocarditis and COVID-19 and a Neuroblastoma Breakthrough
8/26/2022
This week's research roundup includes studies involving Crohn's disease, myocarditis, COVID-19, a potential cure for childhood brain tumors and more. -
Novavax released its second quarter financial results, showing a dramatic adjustment in its sales outlook, while BioNTech prepares to launch two variant-adopted bivalent shots.
-
COVID-19 Update: BA.4 and BA.5 Dominate, Long COVID Effects Continue, CDC Considers Novavax
7/19/2022
As the BA.4/BA.5 Omicron subvariants spread, researchers continue to develop COVID-19 therapies and approaches for preventing or treating the disease. For that and more, continue reading. -
The FDA granted Novavax’s COVID-19 vaccine Emergency Use Authorization after a lengthy and obstacle-riddled journey. It is authorized as a two-dose primary series for adults 18 years and older.
-
Millions of COVID-19 Shots Discarded, while Intermittent Fasting Could Curb Serious Disease
7/8/2022
With COVID-19 vaccination rates dropping, millions of doses are going to waste. Meanwhile, outdoors isn't sure-fire protection but long-term intermittent fasters may be spared severe disease. -
There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.
-
Thursday, a committee of advisors for the CDC voted unanimously for children and teens, ages six to 17 to receive Moderna's COVID-19 vaccine.
-
Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age
6/17/2022
Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to 6 months of age.
-
Moderna's study, dubbed BabyCove, is expected to begin recruiting in September and will include up to 700 babies three to six months of age.
-
UPDATE: In Unanimous Vote, FDA Advisory Committee Recommends Moderna's COVID Vaccine for Kids 6-17
6/14/2022
In a unanimous vote, a panel of FDA advisors voted to recommend the approval of Moderna's COVID-19 vaccine for children between the ages of six and 17 years old. -
On Tuesday, the FDA's Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention to recommend authorization of Novavax’s COVID-19 vaccine.
-
The FDA has expressed worries over four cases of heart inflammation, or myocarditis, that were observed in pivotal clinical trials of Novavax's COVID-19 vaccine.